Table 1.
Baseline characteristics of NSCLC patients.
| Characteristic | Patients (n = 113) |
R Patients (n = 34) |
SD Patients (n = 24) |
PD Patients (n = 55) |
|---|---|---|---|---|
| Sex, No. (%) | ||||
| Male | 87 (77%) | 28 (82.4%) | 14 (58.3%) | 45 (81.8%) |
| Female | 26 (23%) | 6 (17.6%) | 10 (41.7%) | 10 (18.2%) |
| Age, years Median (range) | 65 (36–84) | 65 (45–83) | 64 (35–86) | 66 (48–85) |
| Smoking status | ||||
| Current smokers | 34 (30.1%) | 13 (38.2%) | 7 (29.2%) | 14 (25.5%) |
| Former smokers | 68 (60.2%) | 19 (55.9%) | 14 (58.3%) | 35 (63.6%) |
| Never smokers | 11 (9.7%) | 2 (5.9%) | 3 (12.5%) | 6 (10.9%) |
| Histology | ||||
| Squamous | 42 (37.2%) | 20 (58.8%) | 6 (25%) | 16 (29.1%) |
| Non-Squamous | 71 (62.8%) | 14 (41.2%) | 18 (75%) | 39 (70.9%) |
| PD-L1 tumor expression * | ||||
| Positive | 69 (71.9%) | 22 (71%) | 16 (76.2%) | 31 (70.5%) |
| Low: <1–49% | 35 | 10 | 7 | 15 |
| High: ≥50% | 34 | 12 | 9 | 16 |
| Negative | 27 (28.1%) | 9 (29%) | 5 (23.8%) | 13 (29.5%) |
| Treatment Line | ||||
| First Line | 37 (32.7%) | 16 (47.1%) | 10 (41.7%) | 11 (20%) |
| Second Line | 60 (53.1%) | 13 (38.2%) | 12 (50%) | 35 (63.6%) |
| Third Line and Beyond | 16 (14.2%) | 5 (14.7%) | 2 (8.3%) | 9 (16.4%) |
| Drug | ||||
| Anti-PD-L1 | 28 (24.8%) | 4 (11.8%) | 9 (37.5%) | 15 (27.3%) |
| Anti-PD-1 | 85 (75.2%) | 30 (88.2%) | 15 (62.5%) | 40 (72.7%) |
| Radiological Response | ||||
| Complete Response (CR) | 4 (3.6%) | 4 (11.8%) | - | - |
| Partial Response (PR) | 30 (26.5%) | 30 (88.2%) | - | - |
| Stable Disease (SD) | 24 (21.2%) | - | 24 (100%) | - |
| Progression Disease (PD) | 55 (48.7%) | - | - | 55 (100%) |
* PD-L1 tumor expression was only measured in 96 patients, and the percentages were calculated based on these patients. R, responders; SD, stable disease; PD, progressors. We conducted a chi-square test to compare frequencies, and we have only observed significant differences regarding the histology tumor type (p = 0.003).